Name | 5,6-Dimethylxantheonone-4-acetic acid |
Synonyms | DMXAA CS-1975 vadimezan DMXAA (ASA404,Vadimezan) 5,6-dimethylxanthenoneacetic acid 5,6-Dimethylxanthenone-4-acetic acid 5,6-Dimethylxantheonone-4-acetic acid (5,6-DIMETHYL-9-OXO-XANTHEN)-4-ACETIC ACID 5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid (5,6-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid |
CAS | 117570-53-3 |
InChI | InChI=1/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19) |
Molecular Formula | C17H14O4 |
Molar Mass | 282.29 |
Density | 1.321±0.06 g/cm3(Predicted) |
Melting Point | 259-261 °C |
Boling Point | 520.9±50.0 °C(Predicted) |
Flash Point | 197.1°C |
Solubility | DMSO: 17 mg/mL, soluble |
Vapor Presure | 0Pa at 20℃ |
Appearance | light brown (solid) |
Color | light brown |
pKa | 4.21±0.10(Predicted) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months. |
Refractive Index | 1.633 |
MDL | MFCD00870555 |
Physical and Chemical Properties | Solubility: DMSO: 17 mg/mL, soluble storage condition: 2-8℃ WGK Germany:3 RTECS:ZD5536200 |
In vitro study | In Vitro, DMXAA(ASA404) inhibited purified DT-diaphorase with IC50 of 62.5 μm and K I of 20 μm. DMXAA(ASA404) acts on DLD-1 human colon cancer cells to inhibit DT-diaphorase activity with IC50 of 49.6 μm, but has no significant effect on cytochrome b5 reductase and cytochrome P450 reductase. DMXAA(ASA404) is an antiviral drug that acts on RAW 264.7 macrophages to inhibit VSV-induced cytotoxicity and also inhibits influenza virus replication. Recent studies have shown that DMXAA(ASA404) acts on several kinase members of VEGFR, such as VEGFR2 signals in human umbilical vein endothelial cells, and has a non-immunomodulatory inhibitory effect. |
In vivo study | DMXAA(ASA404) significantly delays chemical carcinogen-induced cell growth, increases tumor doubling time, and increases the time from treatment to euthanasia. DMXAA(ASA404) treatment of tumor-bearing animals increased mean tumor doubling time, mean tumor tripling time, and mean time from treatment to euthanasia by 4.4-, 1.8- 2.7-Times. DMXAA(ASA404) treatment significantly protected C57BL/6J mice infected with H1N1 Influenza PR8 virus adapted to 200 p. F. u. Mice, resulting in a survival rate of 60%, while the survival rate of the control group was only 20%. |
Risk Codes | R22 - Harmful if swallowed R50/53 - Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. |
Safety Description | S60 - This material and its container must be disposed of as hazardous waste. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. |
UN IDs | UN 3077 9/PG 3 |
WGK Germany | 3 |
RTECS | ZD5536200 |
biological activity | DMXAA (Vadimezan) is a vascular disrupting agent (VDA) and a DT-diaphorase competitive inhibitor. Ki is 20 μM and IC50 is 62.5 μM in cell-free test. DMXAA (Vadimezan) is also a STING agonist with potential antitumor activity. DMXAA (Vadimezan) can effectively induce the expression of IFN-β and TNF-α in vitro, but has relatively low effect on TNF-α. DMXAA (Vadimezan) has antiviral activity. Phase 3. |
Target | Value |
DT-diaphorase (Cell-free assay) | 20 μM(Ki) 20 μM(Ki) |